Review Article

Breakpoints for the Classification of Anti-Candida Compounds in Antifungal Screening

Danielle da Nóbrega Alves, Alana Rodrigues Ferreira, Allana Brunna Sucupira Duarte, Ana Karoline Vieira Melo, Damião Pergentino de Sousa, and Ricardo Dias de Castro

1Department of Clinic and Social Dentistry, Graduate Program in Natural and Synthetic Bioactive Products (PgPNSB), Center for Health Sciences, Federal University of Paraíba, João Pessoa, PB, Brazil
2Graduate Program in Natural and Synthetic Bioactive Products (PgPNSB), Center for Health Sciences, Federal University of Paraíba, João Pessoa, PB, Brazil
3Graduate Program in Dentistry (PPGO), Center for Health Sciences, Federal University of Paraíba, João Pessoa, PB, Brazil
4Department of Pharmaceutical Sciences, Center for Health Sciences, Federal University of Paraíba, João Pessoa, PB, Brazil

Correspondence should be addressed to Ricardo Dias de Castro; rcastro@ccs.ufpb.br

Received 17 November 2020; Revised 19 February 2021; Accepted 21 March 2021; Published 7 April 2021

Academic Editor: Wen-Wu Li

Copyright © 2021 Danielle da Nóbrega Alves et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction. The absence of a standardized classification scheme for the antifungal potency of compounds screened against Candida species may hinder the study of new drugs. This systematic review proposes a scheme of interpretative breakpoints for the minimum inhibitory concentration (MIC) of bioactive compounds against Candida species in in vitro tests. Materials and Methods. A literature search was conducted in the PubMed, Scopus, Web of Science, Lilacs, and SciFinder databases for the period from January 2015 to April 2020. The following inclusion criterion was used: organic compounds tested by the microdilution technique according to the Clinical and Laboratory Standards Institute protocol against reference strains of the genus Candida. A total of 545 articles were retrieved after removing duplicates. Of these, 106 articles were selected after applying the exclusion criteria and were evaluated according to the number of synthesized molecules and their chemical classes, the type of strain (reference or clinical) used in the antifungal test, the Candida species, and the MIC (in μg/mL) used.

Results. The analysis was performed based on the median, quartiles (25% and 75%), maximum, and minimum values of four groups: all strains, ATCC strains, C. albicans strains, and C. albicans ATCC strains. The following breakpoints were proposed to define the categories: MIC < 3.515 μg/mL (very strong bioactivity); 3.516-25 μg/mL (strong bioactivity); 26-100 μg/mL (moderate bioactivity); 101-500 μg/mL (weak bioactivity); 500-2000 μg/mL (very weak bioactivity); and >2000 μg/mL (no bioactivity).

Conclusions. A classification scheme of the antifungal potency of compounds against Candida species is proposed that can be used to identify the antifungal potential of new drug candidates.

1. Introduction

The increased prevalence of serious infections caused by Candida species has driven the search for new molecules with antifungal effects and potential for clinical use [1]. Because they are commensal, these microorganisms are especially associated with infections in immunocompromised individuals, resulting in problems that are difficult to solve and require adequate therapy for successful treatment [2]. Few antifungal drugs are available, and the continuous emergence of resistant strains is the greatest challenge related to treatment [3]. The main drugs used to treat fungal infections belong to the classes of polyenes (amphotericin B), pyrimidines (5-fluorocytosine), azoles (fluconazole, voriconazole, itraconazole, etc.), and echinocandins (caspofungin and micafungin) [4]. The main
resistance mechanisms include drug efflux pumps, decreased cell permeability to drugs, alteration of the drug-binding site, and biofilm formation, which hinder drug permeability. Resistance to azoles and echinocandins is frequently reported in the scientific literature [5].

Clinical trials elucidating the effects of new antifungal drugs are still scarce. Some clinical studies have assessed the associations of drugs that are already recognized and available on the market [6, 7]. Combinations of these drugs represent strategies for achieving pharmacological synergism and promoting the treatment of persistent infections. To evaluate new treatments for infections caused by Candida species, investigations generally consider the use of drugs already known to be effective in groups of people with specific morbidity profiles, such as premature infants [8] and individuals with clinical features of recurrent and severe infections [9, 10].

The synthesis of antifungal compounds is an important strategy for obtaining new antifungal drugs with efficacy similar or superior to that observed for available drugs. The discovery of new therapeutic agents with different mechanisms of action allows us to broaden the spectrum of action against resistant microorganisms. In general, scientific studies aimed at synthesizing new antifungal agents evaluate the effects of these molecules using different methodological protocols, which include initial studies to determine their minimum inhibitory concentrations (MICs) in agar diffusion and broth microdilution tests. Often, these protocols are modified in terms of cell concentrations, the type of culture medium, and the microorganisms used, among others. These variations complicate interpretation of the results and advances in knowledge about the effects of compounds on fungal cells.

This difficulty indicates that research on new drugs followed by antifungal evaluations would benefit from the establishment of standardized methods to enable comparisons and further knowledge gains. The establishment of breakpoints to classify the antifungal potential of new compounds is essential to guide the performance of new synthesis protocols and/or antifungal evaluation assays. However, the scientific literature does not include a proposal for the definition of breakpoints for new organic molecules. Often, researchers classify the antifungal potential of new compounds based on an empirical analysis of results obtained for MICs. Available guidelines proposed by the Clinical and Laboratory Standards Institute (CLSI) [11] and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) [12] offer parameters for the classification of substances intended for clinical use. However, breakpoints that can be applied in the search for new molecules with potential for in vivo clinical evaluations and in substance improvement to achieve its best biological profile must be established, especially in antimicrobial screening. The objective of this study is to propose a classification scheme of the antifungal potency of new compounds with activity against Candida.

2. Methods

2.1. Study Question. This systematic review was carried out to address the specific question, “What are the MIC breakpoints for interpretation of the anti-Candida activity of new organic molecules?”

2.2. Eligibility Criteria. Systematic screening of articles was performed by four independent examiners according to the following inclusion criteria.

2.2.1. Biological Activity. The article examined the effects of synthetic molecules with anti-Candida (reference ATCC) activity based on their MIC values (µg/mL) obtained by the microdilution technique. To maintain standardization in the analysis, grouped MIC values (e.g., MIC50, MIC60, or MIC90) were not included.

2.2.2. Study Design. The article reported an in vitro study evaluating antifungal activity against Candida species.

2.2.3. Methodological Quality. The article utilized methods recommended by the CLSI to determine MICs using the microdilution technique (studies using a growth inhibition zone/disc diffusion assay were not included). Study designs, sample representativeness, validity, reproducibility, losses, biases, the accuracy of methods, and outcomes were carefully investigated [13].

2.2.4. Language. No restriction on the language of publication was applied.

2.3. Exclusion Criteria

(1) The study tested organic molecules available for clinical use with improved physical and chemical properties, such as those in the form of nanoparticles and nanocomposites

(2) The study did not precisely define MIC values

(3) The results are reported in molarity values

2.4. Search Strategy and Study Selection. This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for systematic reviews [14, 15]. Four examiners conducted the search independently in the PubMed, Scopus, Web of Science, Lilacs, and SciFinder databases. Articles published from January 2015 to April 2020 were searched comprehensively, with no restrictions on the publication language. The MeSH terms used for the search were “agents, antifungal,” “therapeutic fungicides,” “fungicidi,” “fungicida,” “fungico,” “fungicos,” “antifungal agents,” “antifungal,” “therapeutic,” “antibiotics, antifungal,” “antibiotics, antifungals,” “antibiotics, antimycotics,” “antifungal antibiotics,” “therapeutic,” “fungicides chemistry,” “fungicides/therapeutic,” “fungicides, industrial,” “fungicides, industrial,” “industrial fungicides,” “Candida,” “Candida albicans,” “Candida/analysis,” “Candida/chemistry,” “Candida/drug effects,” “Candida/infection,” “Candida albicans,” “Candida albicans/analysis,” “Candida albicans/chemistry,” “Candida/analysis,” “Candida/chemistry,” “Candida/drug effects,” “Candida/infection,” “Candida albicans,” “Candida albicans/analysis,” “Candida albicans/chemistry,” “Candida/analysis,” “Candida/chemistry,” “Candida/drug effects,” “Candida/infection,” “Candida albicans,” “Candida albicans/analysis,” “Candida albicans/chemistry,” “Candida/analysis,” “Candida/chemistry,” “Candida/drug effects,” “Candida/infection,” “Candida albicans,” “Candida albicans/analysis,” “Candida albicans/chemistry,” “Candida/analysis,” “Candida/chemistry,” “Candida/drug effects,” “Candida/infection,” “Candida albicans,” “Candida albicans/analysis,” “Candida albicans/chemistry,” “Candida/analysis,” “Candida/chemistry,” “Candida/drug effects,” “Candida/infection,” “Candida albicans,” “Candida albicans/analysis,” “Candida albicans/chemistry,” “Candida/analysis,” “Candida/chemistry,” “Candida/drug effects,” “Candida/infection,” “Candida albicans,” “Candida albicans/analysis,” “Candida albicans/chemistry,” “Candida/analysis,” “Candida/chemistry,” “Candida/drug effects,” “Candida/infection,” “Candida albicans,” “Candida albicans/analysis,” “Candida albicans/chemistry,” “Candida/analysis,” “Candida/chemistry,” “Candida/drug effects,” “Candida/infection,” “Candida albicans,” ”Organic Synthesis Methods,” “Method, Organic Synthesis,”
“Methods, Organic Synthesis,” “Organic Synthesis,” “Organic Syntheses,” “Syntheses, Organic,” “Synthesis, Organic.” Boolean operators “AND” and “OR” were used to combine the search terms (Table 1).

After searching the databases, the articles retrieved were imported into EndNote X9, and duplicate articles were removed. Full texts were read after applying the eligibility criteria in cases where the titles and abstracts did not allow exclusion. A third examiner resolved any disagreement between the two reviewers. The data were extracted into an individual spreadsheet to gather the following information: the quantities and chemical classes of the molecules, the type of strain (reference or clinical), the type of Candida species, and the MIC.

2.5. Data Analysis. The data from the studies were analyzed based on MIC values (µg/mL) and classified according to descriptive statistical parameters; quartiles were calculated using Excel 365.

3. Results

A total of 874 articles were identified, and after removing duplicates, 545 documents remained. After reading the full articles, 106 studies were selected, while those that were unrelated to the synthesis of organic compounds and their testing according to the CLSI protocol against the reference strains of the genus Candida were excluded. Studies were also excluded for not precisely reporting MICs (n = 3 studies), presenting the results in molarity values (n = 18 studies), or using formulations in the form of either nanoparticles (n = 3 studies) or nanocomposites (n = 1 study). We additionally excluded studies combining these characteristics, such as those testing compounds in the form of nanoparticles and presenting the results as molarity values (n = 1 study) and those testing molecules in the form of nanoparticles without defining the precise value of the MIC (n = 1 study). Thus, a total of 27 studies were excluded from the analysis among the 106 articles selected in the previous step. From the remaining studies, 1046 evaluated molecules were considered. The selection process according to PRISMA recommendations is depicted in the flowchart shown in Figure 1 [15].

Table 2 shows the MIC values (µg/mL) of the substances eligible for this study. Because the data did not present a normal distribution, they were organized according to descriptive statistical measures: the median, quartiles (25% and 75%), and the maximum and minimum values. This analysis was performed in four groups: group 1, all strains (n = 2199); group 2, all ATCC strains (n = 2005); group 3, all C. albicans strains (n = 1147); and group 4, all C. albicans ATCC strains (n = 969).

Different descriptive analyses yielded similar values. Based on the data above, a classification of the MICs of synthetic compounds into six categories was proposed: very strong bioactivity, strong bioactivity, moderate bioactivity, weak bioactivity, very weak bioactivity, and no bioactivity (Table 3).

The first- and second-quartile values of the MICs of substances with activity against C. albicans ATCC strains and all ATCC strains were higher than those of substances with activity against all strains. Thus, to cover substances with the best results against strains requiring higher MIC values, the categories in Table 3 were defined based on the highest MIC values found. In addition, after observing that the third quartile covered a very wide interval (MICs greater than 100 µg/mL and less than 2000 µg/mL), we further split this quartile into molecules with MICs between 100 and 500 µg/mL, which were classified as weak, and molecules with MICs between 500 and 2000 µg/mL, which were classified as very weak. This split prevented the inclusion of substances with an up to 20-fold MIC difference in the same category.

The consistency of the proposed classification can be demonstrated based on an MIC analysis of molecules such as fluconazole, itraconazole, voriconazole, amphotericin B, and caspofungin because they have been used as positive controls in several studies [16–20] and would be classified as very strong according to Table 3. The above classification was proposed based only on the MIC values of organic molecules; therefore, this classification should not be the only parameter considered in the analysis of a substance or drug as other relevant aspects should be considered, such as toxicity, cost, and availability.

All articles analyzed were classified as in vitro studies published from January 2015 to April 2020 and met the inclusion criteria. Table 1S (supplementary material) describes the characteristics of and the data collected from the selected studies.

4. Discussion

Compared to the development of other drugs, the design of antifungal drugs is more complex because fungi are eukaryotes, and many of the potential targets for therapy are also found in humans, resulting in a higher risk of toxicity [21]. Thus, the search for new chemical agents with high antimicrobial activity is incessant because the development of new antimicrobial drugs will expand the therapeutic arsenal available to the population, especially for the treatment of infections resistant to currently available drugs [22].

The protocols available to evaluate the antifungal activity of chemicals include the guidelines proposed by the CLSI [11] and EUCAST [12], both of which adopt the broth microdilution method but have some methodological differences and are recognized as independent proposals for the interpretation of fungal sensitivity. The CLSI guidelines are widely applied in the USA and used by the Food and Drug Administration for approval of new drugs in the country. The EUCAST guidelines were developed to standardize MIC breakpoints throughout Europe [23, 24]. However, several other methods can also be used to determine antifungal susceptibility, such as disc diffusion, stainless steel cylinders, well agar diffusion, and macrodilution [25]. This diversity of methods adopted by researchers had led to considerable variation in how results are reported, which complicates...
### Table 1: Search strategies in the bibliographic databases used to retrieve the articles for this systematic review.

| Database (since 2015) | Search strategy (descriptors and combinations with Boolean operators) |
|-----------------------|---------------------------------------------------------------------|
| **PubMed**            | #1 search: (((((((((((((((((agents, antifungal) OR (therapeutic fungicides)) OR (fungicid(,)) OR (fungicide)) OR (fungico)) OR (fungicus)) OR (antifungal agents)) OR (antifungal)) OR (therapeutic)) OR (antibiotics, antifungal)) OR (antibiotics, antimycotics)) OR (antifungal antibiotics)) OR (therapeutic)) OR (fungicides chemistry)) OR (fungicides/therapeutic)) OR (fungicides, industrial)) OR (fungicides, industrial)) OR (industrial fungicides). Filters: full texts in the last 5 years #2 search: (((("candida") OR (candida/albicans)) OR (candida/analysis)) OR (candida/chemistry)) OR (candida/drug effects)) OR (candida/albicans)) OR (candida/albicans/analysis)) OR (candida/albicans/chemistry). Filters: full texts in the last 5 years #3 search: (((("chemical synthesis") OR (synthesis techniques[All Fields])) OR ("Synthesis Technique, Organic") OR ("Synthesis Techniques, Organic") OR ("Technique, Organic Synthesis") OR ("Techniques, Organic Synthesis") OR ("Methods, Organic Synthesis") OR ("Method, Organic Synthesis") OR ("Organic Syntheses") OR ("Syntheses, Organic") OR ("Synthesis, Organic")) AND DOCUMENT TYPES: (Article) AND PUBYEAR > 2015 |
| **Scopus**            | #1 search: (ALL ("chemical synthesis" OR "Method, Organic Synthesis" OR "Synthesis Technique, Organic" OR "Synthesis Techniques, Organic" OR "Technique, Organic Synthesis" OR "Techniques, Organic Synthesis") OR ALL ("Methods of Organic Synthesis" OR "Organic Synthesis Methods" OR "Methods, Organic Synthesis" OR "Organic Synthesis" OR "Organic Syntheses" OR "Syntheses, Organic" OR "Synthesis, Organic")) AND DOCTYPE (ar) AND PUBYEAR > 2015 #2 search: (ALL ("candida") OR ALL ("candida/albicans") OR ALL ("candida tropicalis") OR ALL ("candida glabrata") OR ALL ("candida albicans") OR ALL ("candida/analysis") OR ALL ("candida chemistry") OR ALL ("candida/drug effects") OR ALL ("candida infection") OR ALL ("candida/albicans/analysis") AND DOCTYPE (ar) AND PUBYEAR > 2015 #3 search: (ALL ("Agents,antifungal" OR "antifungal agents" OR "antifungal antibiotics" OR "antibiotics,antifungal" OR "fungicides,therapeutic" OR "therapeutic fungicides" OR "fungicides industrial")) AND DOCTYPE (ar) AND PUBYEAR > 2015 |
| **Web of Science**    | #1 search: (TS = ("agents, antifungal") OR "antifungal agents") OR ("antifungal antibiotics") OR ("antibiotics, antifungal") OR ("fungicides, therapeutic") OR ("therapeutic fungicides") OR ("fungicides industrial").) AND DOCUMENT TYPES: (Article) AND Indexes = SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Tempo estipulado = 2015-2020 #2 search: (TS = ("chemical synthesis" OR "Synthesis Technique, Organic" OR "Synthesis Techniques, Organic" OR "Technique, Organic Synthesis" OR "Techniques, Organic Synthesis" OR "Methods, Organic Synthesis" OR "Method, Organic Synthesis" OR "Organic Syntheses" OR "Syntheses, Organic" OR "Synthesis, Organic")) AND DOCUMENT TYPES: (Article) AND Indexes = SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Tempo estipulado = 2015-2020 #3 search: (TS = ("candida" OR "candida/albicans") OR ("candida tropicalis") OR ("candida glabrata") OR "candida albicans") OR ("candida/analysis") OR ("candida chemistry") OR ("candida/drug effects") OR ("candida infection") OR ("candida/albicans/analysis").) AND DOCUMENT TYPES: (Article) AND Indexes = SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Tempo estipulado = 2015-2020 |
| **Lilacs**            | #1 tw:(tw:(tw:"chemical synthesis")) OR (tw:"Method, Organic Synthesis") OR (tw:"Synthesis Technique, Organic") OR (tw:"Synthesis Techniques, Organic") OR (tw:"Techniques, Organic Synthesis") OR (tw:"Methods, Organic Synthesis") OR (tw:"Method, Organic Synthesis") OR (tw:"Organic Syntheses") OR (tw:"Syntheses, Organic") OR (tw:"Synthesis, Organic") AND (fulltext:"1") AND db:"LILACS") AND (year_cluster:[2015 TO 2020]) #2 tw:(tw:(tw:"candida") OR (tw:"candida/albicans") OR (tw:"candida tropicalis") OR (tw:"candida glabrata") OR (tw:"candida albicans") OR (tw:"candida/analysis") OR (tw:"candida chemistry") OR (tw:"candida/drug effects") OR (tw:"candida infection") OR (tw:"candida/albicans/analysis")) AND (fulltext:"1") AND db:"LILACS") AND (year_cluster:[2015 TO 2020]) #3 tw:(tw:(tw:("Agents,antifungal") OR (tw:"antifungal agents") OR (tw:"antifungal antibiotics") OR (tw:"antibiotics,antifungal") OR (tw:"fungicides,therapeutic") OR (tw:"therapeutic fungicides") OR (tw:"fungicides industrial")))) AND (fulltext:"1") AND db:"LILACS") AND (year_cluster:[2015 TO 2020]) |
| **SciFinder**         | #1 AND #2 AND #3 |
standardization and the selection of products in which more resources should be invested.

From the analysis of the selected studies, we found that most of the evaluated strains used in the studies are reference strains, which is very important for the evaluation of the research results because reference strains are used in product testing, as positive and negative controls, as indicator organisms, or as identification standards, thus ensuring the quality of laboratory activities in microbiological analyses [26, 27].

The CLSI and EUCAST provide breakpoints for antifungal agents already used in clinical practice, i.e., they provide acceptable MIC values for the treatment of fungal infections caused by Candida species [11, 12, 28]. Regarding organic compounds with antifungal potential, the literature does
Table 2: Descriptive analysis of the MIC results (μg/mL) of the selected studies.

|                | Group 1: all ATCC strains | Group 2: all C. albicans strains | Group 3: C. albicans ATCC strains | Group 4: C. albicans ATCC strains |
|----------------|----------------------------|----------------------------------|----------------------------------|----------------------------------|
| Minimum value  | 0.0078                     | 0.0078                           | 0.0078                           | 0.0078                           |
| First quartile | 1.95                       | 2                                | 1.95                             | 3.515                            |
| Second quartile| 16                         | 25                               | 16                               | 25                               |
| Third quartile | 100                        | 100                              | 64                               | 100                              |
| Maximum value  | 2000                       | 2000                             | 2000                             | 2000                             |

Table 3: Established parameters based on the minimum inhibitory concentrations of molecules synthesized for anti-Candida activity.

| MIC range         | Intensity of antifungal activity | Score |
|-------------------|----------------------------------|-------|
| <3.515μg/mL       | Very strong bioactivity          | +++++ |
| 3.516-25μg/mL     | Strong bioactivity               | ++++  |
| 26-100μg/mL       | Moderate bioactivity             | +++   |
| 101-500μg/mL      | Weak bioactivity                 | ++    |
| 500-2000μg/mL     | Very weak bioactivity            | +     |
| >2000 μg/mL       | No bioactivity                   | -     |

not present a standardized classification for the interpretation of their bioactivity results, which may hinder accurate evaluations of the antifungal potential of new compounds as well as the identification of potentially promising structures. In addition, MIC values considered high for a new molecule may point to new chemical modifications to the substance that may increase its pharmacological potency. In addition to the verification of MIC values, the determination of the minimum fungicidal concentration (CFM) contributes to a better understanding of the antifungal activity profiles of compounds. The discovery of new drugs with fungicidal activity can improve the treatment of immunocompromised individuals with persistent and serious infections [4].

The proposal of interpretive breakpoints is important for the determination of the antifungal potency of new organic compounds. Thus, in studies aimed at identifying candidates for antifungal drugs, as well as in screens against Candida species, this classification will be decisive for the selection of chemical structures with the best bioactivity, the structural groups responsible for antifungal activity (pharmacophoric groups), or structural groups that potentiate bioactivity or promote inactivity; this information will support the search for substances with high pharmacological potency [29].

Some studies have proposed breakpoints for the activity of plant extracts against Candida species [30–33]. However, considering the complexity of the chemical compositions of these products, the results obtained in evaluations of pure compounds should be interpreted based on other criteria, and new studies must be performed to establish a classification of breakpoints for complex mixtures of natural products. Popiolek et al. [34] proposed a classification of the antifungal bioactivity of 3-hydroxy-2-naphthohydrazone derivatives against a number of microorganisms, such as bacteria, filamentous fungi, and yeasts, including Candida species. In their proposed classification, no bioactivity was defined by an MIC > 1000 μg/mL; mild bioactivity was defined by an MIC of 501-1000 μg/mL, moderate bioactivity was defined by an MIC of 126-500 μg/mL, good bioactivity was defined by an MIC of 26-125 μg/mL, strong bioactivity was defined by an MIC of 10-25 μg/mL, and very strong bioactivity was defined by an MIC < 10 μg/mL. Although this classification was proposed for synthetic molecules, the authors did not indicate the criteria used to establish the categories. Therefore, we consider establishing breakpoints based on global research investigating the activity of new compounds against Candida species with standardization of the methods and fungal strains adopted to be important.

As recommended by CLSI protocols [5], the proposal of breakpoints in this study was based on the MIC values (μg/mL) of organic molecules with anti-Candida activity determined using the microdilution technique. Based on an analysis of 106 published scientific articles involving 1046 molecules, six classification categories are proposed (very strong bioactivity, strong bioactivity, moderate bioactivity, weak bioactivity, very weak bioactivity, and no bioactivity), which expand the analysis of the results and suggest compounds with potential for use in new drugs, especially those with MIC values ≤ 100 μg/mL. Notably, however, the molecular structures of compounds with high MIC values can be chemically modified to improve pharmacological potency.

We analyzed groups of molecules based on the type of fungal strain studied (all strains, ATCC strains, C. albicans strains, and C. albicans ATCC strains). The studies reported results mainly for the following species: C. krusei, C. parapsilosis, C. glabrata, C. tropicalis, and C. utilis. These species are often selected because they are associated with infectious processes in humans and have virulence factors associated with greater disease severity [35–37]. Stratification of the results by the type of strain contributes to a better understanding of such results and to the establishment of breakpoints considering the diversity of findings for different situations.

5. Conclusions

MIC analysis of hundreds of antifungal organic compounds allowed the establishment of a classification scheme of their inhibitory potency against Candida species, which will serve as a reference to identify new antifungal compounds and determine their levels of antimicrobial activity. The present proposal will overcome the lack of an efficient classification system to assist in the discovery of candidate compounds for anti-Candida drugs.
Conflicts of Interest

The authors declare no conflict of interest related to publication of this paper.

Supplementary Materials

Table 1S. Data extraction from the included studies. (Supplementary Materials)

References

[1] R. Van Daele, I. Spriet, J. Wauters et al., “Antifungal drugs: what brings the future?,” Medical Mycology, vol. 57, Supplement_3, pp. S328–S343, 2019.

[2] R. Prasad, R. Nair, and A. Banerjee, “Multidrug transporters of Candida species in clinical azole resistance,” Fungal Genetics and Biology, vol. 132, pp. 103252–103252, 2019.

[3] D. S. Perlin, R. Rautemaa-Richardson, and A. Alastruey-Izquierdo, “The global problem of antifungal resistance: prevalence, mechanisms, and management,” The Lancet Infectious Diseases, vol. 17, no. 12, pp. e383–e392, 2017.

[4] N. Robbins, G. D. Wright, and L. E. Cowen, “Antifungal drugs: the current armamentarium and development of new agents,” The Fungal Kingdom, vol. 4, no. 5, pp. 903–922, 2016.

[5] M. C. Arendrup and T. F. Patterson, “Multidrug-resistant Candida: epidemiology, molecular mechanisms, and treatment,” The Journal of Infectious Diseases, vol. 216, suppl_3, pp. S445–S451, 2017.

[6] K. A. Marr, H. T. Schlamm, R. Herbrecht et al., “Combination antifungal therapy for invasive aspergillosis: a randomized trial,” Annals of Internal Medicine, vol. 162, no. 2, pp. 81–89, 2015.

[7] J. N. Day, T. T. H. Chau, M. Wolbers et al., “Combination antifungal therapy for Cryptococcal meningitis,” New England Journal of Medicine, vol. 368, no. 14, pp. 1291–1302, 2013.

[8] J. Autmiguzine, P. B. Smith, K. Prather et al., “Effect of fluconazole prophylaxis on Candida fluconazole susceptibility in premature infants,” Journal of Antimicrobial Chemotherapy, vol. 73, no. 12, pp. 3482–3487, 2018.

[9] X. Zhou, T. Li, S. Fan et al., “The efficacy and safety of clotrimazole vaginal tablet vs. oral fluconazole in treating severe vulvovaginal candidiass,” Mycoses, vol. 59, no. 7, pp. 419–428, 2016.

[10] J.-F. Timsit, E. Azoulay, C. Schwebel et al., “Empirical micafungin treatment and survival without invasive fungal infection in adults with ICU-acquired sepsis, Candida colonization, and multiple organ failure: the EMPIRICUS randomized clinical trial,” JAMA, vol. 316, no. 15, pp. 1555–1564, 2016.

[11] CLSI Clinical and Laboratory Standards Institute, Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard, C. L. S. I. Wayne, Ed., PA, USA, 2008.

[12] M. C. Arendrup, M. Cuenca-Estrella, C. Lass-Flörl, W. Hope, and EUCAST-AFST, “EUCAST technical note on the EUCAST definitive method EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST),” Clinical Microbiology and Infection, vol. 18, no. 7, pp. E246–E247, 2012.

[13] F. G. Fowkes and P. M. Fulton, “Critical appraisal of published research: introductory guidelines,” BMJ: British Medical Journal, vol. 302, no. 6785, pp. 1136–1140, 1991.

[14] A. Liberati, D. G. Altman, J. Tetzlaff et al., “The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration,” Journal of Clinical Epidemiology, vol. 62, no. 10, pp. e1–e34, 2009.

[15] L. C. Maia and A. G. Antonio, “Systematic reviews in dental research. A guideline,” Journal of Clinical Pediatric Dentistry, vol. 37, no. 2, pp. 117–124, 2012.

[16] M. H. Afsarian, M. Farjam, E. Zarenehazd, S. Behrouz, and M. N. S. Rad, “Synthesis, antifungal evaluation and molecular docking studies of some tetrazole derivatives,” Acta Chimica Slovenica, vol. 66, no. 4, pp. 874–887, 2019.

[17] X. Cao, Y. Xu, Y. Cao et al., “Design, synthesis, and structure-activity relationship studies of novel thienopyrroloidone derivatives with strong antifungal activity against _Aspergillus fumigates_,” European Journal of Medicinal Chemistry, vol. 102, pp. 471–476, 2015.

[18] L. N. de Araújo Neto, M. do Carmo Alves de Lima, J. F. de Oliveira et al., “Synthesis, cytotoxicity and antifungal activity of 5-nitro-thiophene- thiosemicarbazones derivatives,” Chemico-Biological Interactions, vol. 272, pp. 172–181, 2017.

[19] N. P. de Sá, L. F. J. de Paula, L. F. F. Lopes et al., “In vivo and in vitro activity of a bis-aryldienecyclo-alkanone against fluconazole-susceptible and -resistant isolates of _Candida albicans_,” Journal of Global Antimicrobial Resistance, vol. 14, pp. 287–293, 2018.

[20] R. Elias, R. I. Benhamou, Q. Z. Jaber et al., “Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles,” European Journal of Medicinal Chemistry, vol. 179, pp. 779–790, 2019.

[21] S. Campoy and J. L. Adrio, “Antifungals,” Biochemical Pharmacology, vol. 133, pp. 86–96, 2017.

[22] C. Dhivy, S. A. A. Vandarkuzhali, and N. Radha, “Antimicrobial activities of nanostructured polyanilines doped with aromatic nitro compounds,” Arabian Journal of Chemistry, vol. 12, no. 8, pp. 3785–3798, 2019.

[23] M. A. Pfäller, D. Andes, D. J. Diekema, A. Espinel-Ingroff, D. Sheehan, and CLSI Subcommittee for Antifungal Susceptibility Testing, “Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and _Candida_ : Time for harmonization of CLSI and EUCAST broth microdilution methods,” Drug Resistance Updates, vol. 13, no. 6, pp. 180–195, 2010.

[24] A. Wolfensberger, H. Sax, R. Weber, R. Zbinden, S. P. Kuster, and M. Hombach, “Change of antibiotic susceptibility testing guidelines from CLSI to EUCAST: influence on cumulative hospital antibiograms,” PLoS One, vol. 8, no. 11, pp. e79130–e79130, 2013.

[25] E. A. Ostrosky, M. K. Mizumoto, M. E. L. Lima, T. M. Kaneko, S. O. Nishikawa, and B. R. Freitas, “Métodos para avaliação da atividade antimicrobiana e determinação da Concentração Mínima Inibitória (CMI) de plantas medicinais,” Revista Brasileira de Farmacognosia, vol. 18, no. 2, pp. 301–307, 2008.

[26] L. Wu, Q. Sun, P. Desmeth et al., “World Data Centre for Microorganisms: an information infrastructure to explore and utilize preserved microbial strains worldwide,” Nucleic Acids Research, vol. 45, no. D1, pp. D611–D618, 2017.

[27] C. D. O. Rosas, J. M. Rodrigues, M. H. C. D. L. Cruz et al., “Microbiological reference material (bacterial and fungal domains): definition, production rules, use and need for establishment in Brazil,” Brazilian Journal of Food Technology, vol. 22, 2019.
[28] E. L. Berkow, S. R. Lockhart, and L. Ostrosky-Zeichner, “Antifungal susceptibility testing: current approaches,” *Clinical Microbiology Reviews*, vol. 33, no. 3, 2020.

[29] K. C. Howard, E. K. Dennis, D. S. Watt, and S. Garneau-Tsodikova, “A comprehensive overview of the medicinal chemistry of antifungal drugs: perspectives and promise,” *Chemical Society Reviews*, vol. 49, no. 8, pp. 2426–2480, 2020.

[30] F. B. Holetz, G. L. Pessini, N. R. Sanches, D. A. G. Cortez, C. V. Nakamura, and B. P. Dias Filho, “Screening of some plants used in the Brazilian folk medicine for the treatment of infectious diseases,” *Memórias do Instituto Oswaldo Cruz*, vol. 97, no. 7, pp. 1027–1031, 2002.

[31] R. D. S. Pedroso, B. L. Balbino, G. Andrade et al., “In vitro and in vivo anti-*Candida* spp. activity of plant-derived products,” *Plants*, vol. 8, no. 11, p. 494, 2019.

[32] A. Sartoratto, A. L. M. Machado, C. Delarmelina, G. M. Figueira, M. C. T. Duarte, and V. L. G. Rehder, “Composition and antimicrobial activity of essential oils from aromatic plants used in Brazil,” *Brazilian Journal of Microbiology*, vol. 35, no. 4, pp. 275–280, 2004.

[33] D. Silva, H. Diniz-Neto, L. Cordeiro et al., “(R)-(+) β-Citronellol and (S)-(−) β-citronellol in combination with amphotericin B against *Candida* spp.,” *International Journal of Molecular Sciences*, vol. 21, no. 5, pp. 1785–1785, 2020.

[34] Ł. Popiołek, K. Paruch, P. Patrejko, A. Biernasiuk, and M. Wujec, “New 3-hydroxy-2-naphthoic hydrazide derivatives: thiosemicarbazides and 1,2,4-triazole-3-thiones, their synthesis and in vitro antimicrobial evaluation,” *Journal of the Iranian Chemical Society*, vol. 13, no. 10, pp. 1945–1951, 2016.

[35] N. F. Aldardeer, H. Albar, M. Al-Attas et al., “Antifungal resistance in patients with Candidaemia: a retrospective cohort study,” *BMC Infections Diseases*, vol. 20, no. 1, pp. 55–57, 2020.

[36] P. G. Pappas, M. S. Lionakis, M. C. Arendrup, L. Ostrosky-Zeichner, and B. J. Kullberg, “Invasive candidiasis,” *Nature Reviews Disease Primers*, vol. 4, no. 1, pp. 1–20, 2018.

[37] L. Kunyeit, N. K. Kurrey, K. A. Anu-Appaiah, and R. P. Rao, “Probiotic yeasts inhibit virulence of non-albicans *Candida* species,” *MBio*, vol. 10, no. 5, pp. e02307–e02319, 2019.